Why BriaCell Therapeutics (BCTX) Stock Is Down 40%
BriaCell Therapeutics shares are trading lower by 40% Thursday afternoon. The company announced the pricing of a $5.5 million ...
T-Net12h
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...
bovnews13h
Briacell Therapeutics Corp (BCTX) Stock: Unveiling Its Hidden Strengths
Briacell Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.03%. The profit margin, also known as the revenue ratio or gross profit ...
Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics
BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...
BriaCell Prices 7.4 Mln Public Offering, To Raise $5.5 Mln
BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, Thursday announced the pricing of an underwritten public ...
manilatimes22h
Nutanix Announces Pricing of $750 Million 0.50% Convertible Senior Notes
The notes will be senior, unsecured obligations of Nutanix. The notes will bear interest at a rate of 0.50% per year. Interest will be payable semi-annually in arrears on June 15 and December 15 of ...
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...